Cargando…

Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia

OBJECTIVE: To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. METHODS: Selected patients (n=43) with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated H...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Xu, Ying-Ying, Zhang, Qi-Lin, Luo, Wei-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907496/
https://www.ncbi.nlm.nih.gov/pubmed/29849847
http://dx.doi.org/10.1155/2018/7365148
_version_ 1783315543897407488
author Liu, Jing
Xu, Ying-Ying
Zhang, Qi-Lin
Luo, Wei-Feng
author_facet Liu, Jing
Xu, Ying-Ying
Zhang, Qi-Lin
Luo, Wei-Feng
author_sort Liu, Jing
collection PubMed
description OBJECTIVE: To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. METHODS: Selected patients (n=43) with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated Hospital of Soochow University between August 2008 and February 2014, were grouped by age, one subset (n=14) ≥80 years old and another (n=29) <60 years old. Each group scored similarly in degrees of pain registered by the visual analogue scale (VAS). Dosing, efficacy, and safety of BTX-A injections were compared by group. RESULTS: Mean dosages of BTX-A were 91.3 ± 25.6 U and 71.8 ± 33.1 U in older and younger patients, respectively (t=1.930,  p=0.061). The median of the VAS score in older patients at baseline (8.5) declined significantly at 1 month after treatment (4.5) (p=0.007), as did that of younger patients (8.0 and 5.0, resp.) (p=0.001). The median of the D values of the VAS scores did not differ significantly by group (older, 2.5; younger, 0; Z=−1.073, p=0.283). Two patients in each group developed minor transient side effects (p=0.825). Adverse reactions in both groups were mild, resolving spontaneously within 3 weeks. CONCLUSIONS: BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old).
format Online
Article
Text
id pubmed-5907496
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59074962018-05-30 Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia Liu, Jing Xu, Ying-Ying Zhang, Qi-Lin Luo, Wei-Feng Pain Res Manag Clinical Study OBJECTIVE: To assess the therapeutic efficacy and safety of botulinum toxin type A (BTX-A) for treating idiopathic trigeminal neuralgia (ITN) in patients ≥80 years old. METHODS: Selected patients (n=43) with ITN, recruited from the neurology clinic and inpatient department of the Second Affiliated Hospital of Soochow University between August 2008 and February 2014, were grouped by age, one subset (n=14) ≥80 years old and another (n=29) <60 years old. Each group scored similarly in degrees of pain registered by the visual analogue scale (VAS). Dosing, efficacy, and safety of BTX-A injections were compared by group. RESULTS: Mean dosages of BTX-A were 91.3 ± 25.6 U and 71.8 ± 33.1 U in older and younger patients, respectively (t=1.930,  p=0.061). The median of the VAS score in older patients at baseline (8.5) declined significantly at 1 month after treatment (4.5) (p=0.007), as did that of younger patients (8.0 and 5.0, resp.) (p=0.001). The median of the D values of the VAS scores did not differ significantly by group (older, 2.5; younger, 0; Z=−1.073, p=0.283). Two patients in each group developed minor transient side effects (p=0.825). Adverse reactions in both groups were mild, resolving spontaneously within 3 weeks. CONCLUSIONS: BTX-A is effective and safe in treating patients of advanced age (≥80 years old) with ITN, at dosages comparable to those used in much younger counterparts (<60 years old). Hindawi 2018-04-05 /pmc/articles/PMC5907496/ /pubmed/29849847 http://dx.doi.org/10.1155/2018/7365148 Text en Copyright © 2018 Jing Liu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Liu, Jing
Xu, Ying-Ying
Zhang, Qi-Lin
Luo, Wei-Feng
Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title_full Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title_fullStr Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title_full_unstemmed Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title_short Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia
title_sort efficacy and safety of botulinum toxin type a in treating patients of advanced age with idiopathic trigeminal neuralgia
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907496/
https://www.ncbi.nlm.nih.gov/pubmed/29849847
http://dx.doi.org/10.1155/2018/7365148
work_keys_str_mv AT liujing efficacyandsafetyofbotulinumtoxintypeaintreatingpatientsofadvancedagewithidiopathictrigeminalneuralgia
AT xuyingying efficacyandsafetyofbotulinumtoxintypeaintreatingpatientsofadvancedagewithidiopathictrigeminalneuralgia
AT zhangqilin efficacyandsafetyofbotulinumtoxintypeaintreatingpatientsofadvancedagewithidiopathictrigeminalneuralgia
AT luoweifeng efficacyandsafetyofbotulinumtoxintypeaintreatingpatientsofadvancedagewithidiopathictrigeminalneuralgia